Pneumococcal meningitis and etanercept—chance or association?

Rheumatoid arthritis is a severe deforming chronic disease which has major implications for mortality and quality of life. Agents with anti-tumour necrosis factor alpha (TNFα) activity are a new modality of therapy, which can significantly reduce the acute inflammation in this condition. However, TN...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infection Vol. 51; no. 2; pp. E49 - E51
Main Authors: Killingley, B., Carpenter, V., Flanagan, K., Pasvol, G.
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-08-2005
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rheumatoid arthritis is a severe deforming chronic disease which has major implications for mortality and quality of life. Agents with anti-tumour necrosis factor alpha (TNFα) activity are a new modality of therapy, which can significantly reduce the acute inflammation in this condition. However, TNFα is a cytokine involved in initiating the protective immune response; consequently, patients receiving this therapy are at increased risk of infection. Etanercept is a recombinant form of the p75 TNF receptor (TNF-RII) dimerised by fusion with a portion of the human IgG1 Fc tail with anti-TNFα activity. We report the first case of a patient with rheumatoid arthritis who developed pneumococcal meningitis whilst on etanercept, suggesting a possible association between etanercept and this severe life threatening infection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Case Study-2
ObjectType-Feature-4
ObjectType-Report-1
ObjectType-Article-3
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2004.08.015